Esophageal involvement and pulmonary manifestations in systemic sclerosis

Arthritis Care and Research

Volumn 45, Issue 4, 2001, Pages 346-354

  Marie, Isabelle ^a,c   Dominique, Stphane ^b   Levesque, Herv ^a   Ducrott, Philippe ^b   Denis, Philippe ^b   Hellot, Marie France ^b   Courtois, Hubert ^a  

^a Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c NONE   (France)

Author keywords

Esophageal involvement; Gastroesophageal reflux; Interstitial lung disease; Pulmonary impairment; Systemic sclerosis

Indexed keywords

CARBON MONOXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION FUNCTION; DISEASE SEVERITY; ESOPHAGUS DISEASE; ESOPHAGUS MANOMETRY; ESOPHAGUS MOTILITY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; MOTOR DYSFUNCTION; PREVALENCE; SYSTEMIC SCLEROSIS;

EID: 0034908297     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200108)45:4<346::aid-art347>3.0.co;2-l     Document Type: Article

References (71)

1. Pulmonary manifestations of scleroderma
2. Organ involvement: Pulmonary
3. Pathologic observations in systemic sclerosis (scleroderma): A study of fifty-eight autopsy cases and fifty-eight matched controls
4. Atteinte pulmonaire au cours de la sclérodermie systémique. I. Pneumopathie interstitielle chronique fibrosante
5. Atteinte pulmonaire au cours de la sclérodermie systémique. II. Hypertension artérielle pulmonaire isolée, cancer bronchopulmonaire, hémorragie alvéolaire
6. The lungs in systemic sclerosis (scleroderma): A review and new information
7. Pulmonary involvement in systemic sclerosis (scleroderma)
8. Scleroderma: Clinical problems. The lungs
9. Interstitial lung disease of systemic sclerosis
10. Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis
11. Predictors of survival in systemic sclerosis (scleroderma)
12. Prediction of five-year survival following presentation with scleroderma: Development of a simple model using three disease factors at first visit
13. D-penicillamine therapy and interstitial lung disease in scleroderma: A long-term follow-up study
14. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis
15. Progressive systemic sclerosis: Mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients
16. Mortality in systemic sclerosis (scleroderma)
17. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis
18. Diffusing capacity of the lung and nifedipine in systemic sclerosis
19. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage
20. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis
21. Isolated diffusing capacity reduction in systemic sclerosis
22. Severe restrictive lung disease in systemic sclerosis
23. Survival with systemic sclerosis (scleroderma): A life-table analysis of clinical and demographic factors in 309 patients
24. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis
25. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis
26. Elevated levels of platelet derived growth factor and transforming growth factor-β1 in bronchoalveolar lavage fluid from patients with scleroderma
27. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: A quantitative study of open lung biopsies
28. Pulmonary involvement in diffuse cutaneous systemic sclerosis: Bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis
29. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis
30. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis
31. Silica induced scleroderma - Clinical and experimental aspects
32. Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma)
33. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis
34. Epidemiology of scleroderma
35. What is the contribution of occupational environmental factors to the occurrence of scleroderma in men?
36. Esophageal motility and pulmonary function in progressive systemic sclerosis
37. Organ involvement: Gut and hepatic manifestations
38. Pulmonary disease in progressive systemic sclerosis: A complication of gastroesophageal reflux and occult aspiration?
39. Gastrointestinal manifestations of progressive systemic sclerosis
40. Gastrointestinal motility disorders in scleroderma
41. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
42. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
43. Manometry of the upper intestinal tract in patients with systemic sclerosis: A prospective study
44. Savary-Miller's new endoscopic grading of reflux-oesophagitis: A simple, reproducible, logical, complete and useful classification
45. Esophageal manometry and 24-hour pH monitoring in the diagnosis of pulmonary aspiration secondary to gastroesophageal reflux
46. Clinical respiratory physiology: Standardized lung function testing. Working party report: Standardization of lung function tests
47. Gastrointestinal manifestations of systemic sclerosis
48. The gastrointestinal manifestations of scleroderma: Pathogenesis and management
49. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis
50. Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis
51. Gastric involvement in systemic sclerosis: A prospective study
52. Prolonged clearance is the primary abnormal reflux parameter in patients with progressive systemic sclerosis and esophagitis
53. Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases
54. Pulmonary aspiration as a consequence of gastroesophageal reflux: A diagnostic approach
55. Simultaneous tracheal and esophageal pH monitoring: Investigating reflux-associated asthma
56. Gastroesophageal reflux in patients with asthma and chronic bronchitis
57. Asthma and gastroesophageal reflux: Acid suppressive therapy improves asthma outcome
58. Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux
59. Gastroesophageal reflux and asthma: A possible reflex mechanism
60. Gastroesophageal reflux and diseases of the respiratory tract: A review
61. Pulmonary fibrosis associated with tracheobronchial aspiration: A study of the frequency of hiatal hernia and gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiology
62. Idiopathic pulmonary fibrosis: Current clinical concepts and challenges in management
63. Diffuse pulmonary fibrosis and hiatus hernia
64. Gastroesophageal reflux and chronic respiratory disease in adults
65. Typical and atypical presentations of gastroesophageal reflux disease: The role of esophageal testing in diagnosis and management
66. Pulmonary symptoms associated with gastroesophageal reflux: Use of ambulatory pH monitoring to diagnose and to direct therapy
67. Gastroesophageal reflux disease and asthma: Diagnosis and management
68. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy
69. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis
70. Comparison of airway responses following tracheal or esophageal acidification in the cat
71. Pulmonary function and gastroesophageal reflux in systemic sclerosis